Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Ni... (ble equity securities. The followin...)

Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent

Date:11/4/2009

ble equity securities.

    The following table includes the GAAP income statement for the three
    and nine month periods ending 2009 and 2008.


                                 THORATEC CORPORATION
                     Condensed Consolidated Statement of Operations
                                     (Unaudited)
                        (in thousands, except for per share data)

                                     Three Months Ended  Nine Months Ended
                                     ------------------  -----------------
                                               September           September
                                                  27,                 27,
                                      October   2008 As  October    2008 As
                                         3,    Adjusted     3,     Adjusted
                                        2009      (1)      2009       (1)
                                        ----     ----      ----      ----
    Product sales                     $87,917  $80,815  $269,442  $227,890
    Cost of product sales              34,185   32,045   110,928    92,460
                                       ------   ------   -------    ------
    Gross profit                       53,732   48,770   158,514   135,430
                                       ------   ------   -------   -------
    Operating expenses:
     Selling, general and
      administrative                   24,226   23,845    82,457    68,338
     Research and development          13,350   13,443    40,862    38,801
     Amortization of purchased
      intangible assets                 2,568    3,295     8,067     9,887
                                        -----    -----     -----     -----
    Total operating expenses           40,144   40,583   131,386   117,026
                                       ------   ------   -------   -------
    Income from operations             13,588    8,187    27,128    18,404
    Other income and (e
'/>"/>
SOURCE  Thoratec Corporation
Copyright©2009 PR Newswire.
All rights reserved 
0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
Related medicine technology :

1. Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
2. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Spherix Reports Second Quarter Earnings
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
11. Biopure Reports on Meeting with the FDA

Post Your Comments:

Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Ni...(ble equity securities. The followin...),Health